FactSet Analysts Rate Cytek Biosciences as Hold

Summary

According to a survey by FactSet analysts, Cytek Biosciences has an average rating of ‘hold’, with an average target price of $6.Trading View

Impact Analysis

The event is classified at the company level, as it directly involves Cytek Biosciences. Analysts have given the company a ‘hold’ rating, which suggests a neutral position on the stock’s immediate prospects. This is supported by recent financial data indicating a 7.6% decline in Q1 2025 revenue and an adjusted EBITDA loss of $5.5 million.Reuters Additionally, the fact that prominent investors like Topline Capital Management have minimal holdings in Cytek and that top analysts are recommending other stocks over Cytek suggests limited confidence in significant upward movement for Cytek’s stock.Market Beat Investors should carefully consider these factors, as the ‘hold’ rating reflects both the potential stability of the stock and the absence of strong upward drivers in the short term. The attendance of Cytek at relevant industry conferences such as the Immunology Annual Meeting could provide future catalysts if positive developments arise from these engagements.Reuters